HOME
[
Click here to subscribe to our weekly newsletter!!
]
Fluoxetine (Prozac, Prozac Weekly, Sarafem)
Monthly Archives of Research Articles
Month
News
Items
Pubmed
Articles
Highlights
August 2003
08.17.03 [396]
08.10.03 [508]
08.03.03 [475]
click
Click here to go to our six-month Anniversary Issue #26 (08/04/03) of our members-only
weekly
newsletter!!
July 2003
07.27.03 [393]
07.20.03 [292]
29
June 2003
27
May 2003
38
April 2003
35
March 2003
38
February 2003
29
driving
•
alcohol withdrawal
•
OCD
•
GABA-A receptors
•
5HT-1A receptors
•
poststroke motor function
•
aggression
•
neonatal exposure
INTERACTIONS
:
general
•
cocaine/dopamine
•
zaprinast
•
CYP2D6
•
haloperidol/Haldol
•
allopregnanolone
SFX
:
weight gain
•
sexual
•
withdrawal
•
agitation
•
insomnia
•
abnormally enlarged breasts (gynecomastia)
•
prolactin
•
extrapyramidal
•
cardiac/QTc
January 2003
01.26.03
01.19.03
01.12.03
01.05.03
30
killing cancer cells: Burkitt lymphoma treatment?
•
aggression [animal]
•
cocaine use
•
borderline personality disorder
•
in animal model of depression [rat]
•
selective mutism
•
brain growth factor needed for antidepressant effect
•
eating disorder
INTERACTIONS
:
estrogen hormones
•
olanzapine/Zyprexa
•
valproic acid/Depakote
•
tramadol/Ultram
SFX
:
anxiety [rat]
•
sexual dysfunction in women
TRIALS
:
with olanzapine/Zyprexa for psychotic depression [n=27 OL]
•
vs psychotherapy [n=450 DBPC]
•
adult ADHD in cocaine users [n=19 OL]
December 2002
12.29.02
12.22.02
12.15.02
12.08.02
12.01.02
28
fibromyalgia
•
sweating in social anxiety
•
OCD
•
probing mechanisms of action
•
brain levels of serotonin and norepinephrine (rat)
•
migraines
•
genetic predictors of response
•
stereoselective effects (rat)
INTERACTIONS
:
phencyclidine/PCP and NMDA receptors
•
P450 effects (rat)
•
phototherapy
•
5HT-2 antagonists (animal)
SFX
:
emotional blunting
•
sleep, driving performance
•
rash
November 2002
11.17.02
11.10.02
11.03.02
45
review: premenstrual dysphoric disorder (PMDD)
•
eating disorders
•
body dysmorphic disorder
•
probing the mechanisms of depression response
•
dual action antidepressants better (rats)
•
vs turmeric (
Curcuma longa
) (mice)
INTERACTIONS
:
pharmacokinetics in children
•
heparin/Lovenox
•
pimozide/Orap
•
SFX
:
review: suicidal ideation
•
bleeding
•
seizures (rats)
TRIALS
:
primary care: treatment of cancer-related depression by algorithm [n=35 OLPC]
•
OCD in children and adolescents [n=43 OLPC]
•
binge-eating [n=60 DBPC]
•
premenstrual dysphoric disorder (PMDD) [n=108 OLPC]
•
autism [n=129 OL]
•
no effects on child after fetal exposure [n=122 OL]
October 2002
10.20.02
10.13.02
10.06.02
33
speed of onset
•
postnatal depression and breast milk
•
depression during pregnancy
INTERACTIONS
:
amantadine in rats
•
amphetamine
SFX
:
hyponatremia and 2D6
•
weight loss in rats
•
manic sx in adults with learning disabilities
TRIALS
:
vs tianeptine [n=178 DB; n=387 DB]
•
sleep and anxiety in depression, vs dothiepine [n=125 DB]
•
pediatric depression [n=219 DBPC]
•
preventing PTSD relapse [n=131 DBPC]
September 2002
09.29.02
09.22.02
09.08.02
09.01.02
33
blood levels
•
breast milk
•
PMDD (premenstrual dysphoric disorder)
•
adding CBT for OCD
•
R-fluoxetine
•
transporter-binding: R-fluoxetine vs escitalopram/Lexapro vs other SSRIs
•
decrease in impulsive behavior in pigeons
•
vs St John's wort
•
personality disorder symptoms
INTERACTIONS
:
oral contraceptives (birth control pills) and unplanned pregnancy
SFX
:
sexual
TRIALS
:
relapse risk: with or without cognitive therapy [n=132 OL]
•
for depression w/anxiety [n=123 OL]
•
for PMDD: 10 vs 20 mg [n=260 SBPC]
•
for depressed methadone maintenance patients [n=49 DBPC]
August 2002
08.25.02
08.11.02
08.04.02
29
pregnancy
•
prescriptions
•
cholesterol and response rate
•
memory
•
treatment-resistant depression
•
tics
INTERACTIONS
:
P450 2D6 inhibition
•
tramadol/Ultram
•
risperidone/Risperdal
SFX
:
mania
•
withdrawal symptoms (vs paroxetine/Paxil)
TRIALS
:
depression and anxiety (vs venlafaxine/Effexor) [n=1454 DBPC]
•
smoking [n=989 DBPC]
•
vs reboxetine [n=381 DBPC]
•
augmentation with lithium or desipramine [n=101]
July 2002
07.28.02
07.21.02
07.14.02
07.07.02
39
marketing
•
PMDD (premenstrual dysphoric disorder)
•
in atypical antipsychotic-induced weight gain
•
beta-1 receptors
•
regulation of serotonin release
•
serotonin-1A receptors
•
augmentation with olanzapine/Zyprexa for psychotic depression
•
augmentation with olanzapine/Zyprexa for treatment-resistant depression
•
vs sertraline/Zoloft
•
mania
•
stress response
•
for autism
•
for aggression
•
augmentation with NMDA antagonists amantadine/Symmetrel and memantine/Ebixa
•
cocaine dependence
INTERACTIONS
:
Ecstacy/MDMA
•
olanzapine/Zyprexa
•
progesterone
SFX
:
sexual
•
urinary retention
•
learning
•
weight
TRIALS
:
vs venlafaxine/Effexor [n=146 DB]
•
vs venlafaxine/Effexor for depression
•
clonazepam augmentation [n=50 DBPC]
•
Prozac Weekly in depression relapse [n=501 DBPC]
June 2002
20
for premenstrual dysphoric disorder
•
blood levels
•
predicting response
•
neuropeptide Y
•
5HT1B receptors
•
for childhood depression
INTERACTIONS
:
loratadine/Claritin
•
tramadol/Ultram
•
phentermine/Adipex
SFX
:
sexual
•
weight loss
•
extrapyramidal
May 2002
42
suicide prevention
•
serotonin receptors
•
estrogen augmentation in perimenopausal depression
•
effect on cholinesterases
•
in post-traumatic OCD
•
versus placebo in brain metabolism
•
treatment response relates to genetic variability of serotonin transporter
INTERACTIONS
:
codeine
•
selegiline/Eldepryl
•
caffeine
•
risperidone/Risperdal
SFX
:
tremor
•
serotonin syndrome
TRIALS
:
geriatric depression [n=242 DBPC]
•
prevention of poststroke depression [n=48, DBPC]
•
versus St. John's wort [n=70 , DBPC]
•
anxious depression [n=22 DBPC]
•
social anxiety disorder [n=60 DBPC]
April 2002
40
comparing SSRIs
•
for stroke
•
switching to Prozac Weekly
•
increase in brain growth factor
•
itching in polycythemia vera
INTERACTIONS
:
St. John's wort and gingko
•
ECT
•
adding bupropion/Wellbutrin
SFX
:
rash
•
withdrawal
•
low sodium
TRIALS
:
premenstrual dysphoric disorder
•
body dysmorphic disorder
•
PTSD
•
depression [review]
March 2002
43
February 2002
22
January 2002
52
---ALL 2001---
401
December 2001
22
November 2001
23
[n=number of subjects in study. OL=open label (nonblinded). SB=single-blind. DB=double-blind. PC=placebo control. SFX=side effects]